Journal
NATURE REVIEWS CANCER
Volume 9, Issue 9, Pages 675-681Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2717
Keywords
-
Categories
Funding
- Bobbie and Leo Fields Family Fund for Medical Research
- Union Temporal de Empresas
Ask authors/readers for more resources
The clonal immunoglobulin idiotype displayed on the surface of most malignant B cells is a patient-and tumour-specific antigen that can be used for therapeutic vaccination. Several studies have confirmed the biological efficacy of soluble protein idiotypic vaccination and two clinical trials have shown the clinical efficacy of this procedure. One study has demonstrated clinical benefit associated with idiotypic vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to the vaccine. While scepticism towards this type of non-toxic medical intervention is mounting, such patient-specific treatments might yet see the light of day through better designed clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available